Augment deep clinical data with comprehensive genomic profiling, fueling your team’s early discovery and translational epidemiology efforts.
COTA’s clinicogenomics product covers:
Data includes both standard of care and emerging biomarkers. Information on emerging biomarkers can enable:
Founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real-world data. COTA curates t-for-purpose, regulatory-grade oncology RWD from structured and unstructured EHR data that is used across the drug development lifecycle.
Our data is ready for analysis and contains clear longitudinal patients journeys that support regulatory submissions and research questions including treatment patterns, real-world outcomes, and comparisons.